Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study

OBJECTIVE: Camrelizumab is a newly developed program-death receptor one inhibitor; the real-world evidence about its application in hepatocellular carcinoma (HCC) treatment is lacking. Therefore, this prospective, multi-center, real-world study evaluated the efficacy and safety of camrelizumab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Ran, Xu, Qingyu, Wang, Qi, Zhang, Qingqiao, Zhou, Weizhong, Cao, Chi, Huang, Xiangzhong, Ji, Honghai, Lv, Penghua, Jiang, Hao, Lu, You, Jin, Yong, Li, Yongjun, Cheng, Long, Wang, Weidong, Xu, Hao, Zhu, Xiaoli, Yin, Guowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378838/
https://www.ncbi.nlm.nih.gov/pubmed/35982962
http://dx.doi.org/10.3389/fonc.2022.816198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378838/
https://www.ncbi.nlm.nih.gov/pubmed/35982962
http://dx.doi.org/10.3389/fonc.2022.816198

Ejemplares similares